Novartis AG ADR (NVS)vsScisparc Ltd (SPRC)
NVS
Novartis AG ADR
$156.08
-0.50%
HEALTHCARE · Cap: $286.29B
SPRC
Scisparc Ltd
$0.83
-2.35%
HEALTHCARE · Cap: $749,460
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8349384% more annual revenue ($56.69B vs $679,000). NVS leads profitability with a 22.5% profit margin vs 0.0%. SPRC trades at a lower P/E of 0.0x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SPRC
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.08
$62.24 premium
Intrinsic value data unavailable for SPRC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SPRC
The strongest argument for SPRC centers on P/E Ratio, Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SPRC
The primary concerns for SPRC are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
SPRC carries more volatility with a beta of 2.55 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Scisparc Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
SciSparc Ltd., a specialized clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. The company is headquartered in Tel Aviv, Israel.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?